Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Moyom Biotechnology specializes in the development of advanced nano-biomaterials and Class III absorbable implants for the global medical aesthetics market. Its flagship product line "Aphranel" features precision-engineered calcium hydroxylapatite fillers with proprietary control over microsphere size and degradation rate. The company has achieved significant regulatory milestones including EU CE marking and approvals across Asia and Latin America. Clinical collaborations with leading global centers are underway to establish long-term safety, efficacy, and best practices in regenerative aesthetic medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Moyom Biotechnology.